CORDIS
EU research results

CORDIS

English EN
Refactoring monoterpenoid indole alkaloid production in microbial cell factories

Refactoring monoterpenoid indole alkaloid production in microbial cell factories

Objective

Plants produce some of the most potent human therapeutics and have been used for millennia to treat illnesses. The monoterpenoid indole alkaloids (MIAs) are plant secondary metabolites that show a remarkable structural diversity and pharmaceutically valuable biological activities with more than 2,000 MIAs derived from the common precursor strictosidine. However, because most MIA chemicals do not have their biosynthetic pathways elucidated and MIA-producing plants are not genetically trackable, MIAs are under-represented in recently introduced medicines. In the consortium for Refactoring of Monoterpenoid Indole Alkaloids in Microbial Cell Factories (MIAMi) our main objective is to develop sustainable microbial production of new human therapies for the benefit of the European biotech industry, human health, and the environment. To do so, MIAMi will i) develop a new approach for MIA biosynthetic pathway discovery in plants founded on supervised learning algorithms based on omics data sampled from > 20 MIA producing plants, ii) contribute to standardisation of bioengineering by development of SOPs for characterisation of > 100 DNA elements for control of gene expression, protein interactions, and sub-cellular localisation, iii) build a public parts repository and Bio-CAD for forward engineering of compartmentalised biosynthetic pathway designs in yeast, and iv) apply automated genome engineering to prototype > 1,000 new-to-nature MIA biosynthetic pathway designs in order to identify robust designs for scale-up microbial MIA production processes, and evaluate the environmental benefits and risks compared to existing value chains. The excellent, interdisciplinary and inter-sectorial consortium will showcase the use of the new approaches and standardised data inventory to produce both commercially available and new-to-market MIAs rauwolscine, tabersonine and alstonine in yeast, and finally test their bioactivity as new cancer and psychosis treatment drug leads.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

DANMARKS TEKNISKE UNIVERSITET

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 438 313,75

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

JOHN INNES CENTRE

United Kingdom

EU Contribution

€ 1 511 371,25

UNIVERSITE DE TOURS

France

EU Contribution

€ 1 165 125

EXPLORA SRL

Italy

EU Contribution

€ 719 250

FUTURE GENOMICS TECHNOLOGIES BV

Netherlands

EU Contribution

€ 853 750

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 341 116,25

AXYNTIS

France

EU Contribution

€ 619 375

Project information

Grant agreement ID: 814645

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2022

Funded under:

H2020-EU.2.1.4.

  • Overall budget:

    € 6 648 301,25

  • EU contribution

    € 6 648 301,25

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark